Non-small cell lung cancer Guideline, version /05. Non-Small Cell Lung Cancer Clinical Practice Guideline
|
|
- Hollie Maxwell
- 5 years ago
- Views:
Transcription
1 Non-Small Cell Lung Cancer Clinical Practice Guideline
2 PATHOLOGIC DIAGNOSIS OF NSCLC Non-Small Cell Lung Cancer (NSCLC) INITIAL EVALUATION Pathology review H&P (include perfmance status + weight loss) CBC/DC; SMAC Hepatitis profile Smoking cessation Chest CT and Abd echo Options (1) Bronchoscopy (2) Pul function (3) Chest MRI (4) PET-CT (5) Bone scan (6) Brain image CLINICAL STAGE Stage IA, peripheral c (T1ab, N0) Mediastinal CT negative (lymph nodes <1 cm) Stage I, peripheral c (T2a, N0); central c (T1ab-T2a, N0); Stage II (T1ab-T2ab, N1; T2b, N0); stage IIB (T3, N0) d Mediastinal CT negative (lymph nodes <1 cm) Stage IIB e (T3 invasion, N0); Stage IIIA e (T4 extension, N0-1; T3, N1) Stage IIIA e (T1-3, N2) Separate pulmonary nodule(s) (Stage IIB, IIIA, IV) Multiple lung cancers Stage IIIB e (T1-3, N3) mediastinal CT positive Contralateral (lymph nodes 1 cm) palpable supraclavicular lymph nodes Stage IIIB e (T4 extension, N2-3) on CT Stage IV (M1a) (pleural pericardial effusion) Stage IV (M1b) Solitary metastasis with resectable lung lesion Stage IV (M1b) Disseminated metastases NSCL-1
3 PRETREATMENT EVALUATION f CLINICAL ASSESSMENT Stage IA (peripheral T1ab, N0) PFTs (if not previously done) Bronchoscopy (intraoperative preferred) Pathologic mediastinal lymph node evaluation g (categy 2B) PET/CT scan h (if not previously done) Negative mediastinal nodes Positive mediastinal nodes Operable Medically inoperable See Initial Treatment and Adjuvant Treatment Definitive RT SABR i See Stage IIIA Stage IIIB Stage IB (peripheral T2a, N0) Stage I (central T1ab T2a, N0) Stage II (T1ab 2ab, N1; T2b, N0) Stage IIB (T3, N0) d PFTs (if not previously done) Bronchoscopy Pathologic mediastinal lymph node evaluation g PET/CT scan h (if not previously done) Brain MRI (Stage II, Stage IB [categy 2B]) Negative mediastinal nodes Positive mediastinal nodes Operable Medically inoperable See Initial Treatment and Adjuvant Treatment Definitive RT ± chemotherapy j See Stage IIIA Stage IIIB Note: Clini c a l s t a g e I A - I I B( T 3, N 0) 轉醫學中心執行縱膈腔淋巴結切片, 並評估是否可以進行手術切除如無法手術切除, 則轉回本院進行 Definitive RT ± chemotherapy NSCL-2
4 INITIAL TREATMENT FINDINGS AT SURGERY ADJUVANT TREATMENT Stage IA (T1ab, N0) Margins negative (R0) Margins positive (R1, R2) Observe Reresection (preferred) RT Surgical explation and resection + mediastinal lymph node dissection systematic lymph node sampling Stage IB (T2a, N0); Stage IIA (T2b, N0) Stage IIA (T1ab-T2a, N1) Stage IIB (T3, N0; T2b, N1) Stage IIIA (T1-3, N2; T3, N1) Margins negative (R0) Margins positive (R1, R2) Margins negative (R0) Margins positive (R1, R2) Margins negative (R0) Margins positive (R1, R2) Observe Chemotherapy in high-risk patients Reresection (preferred) ± chemotherapy RT i,j ± chemotherapy j,p (chemotherapy f stage IIA) Chemotherapy Reresection + chemotherapy Chemadiation + chemotherapy Chemotherapy + RT Chemadiation + chemotherapy Surveillance Note: clinical stage IA IIIA 術後依病理報告, 決定 : (1) 觀察 ;(2) R/T;(3)C/T;(4)CCRT NSCL-3
5 CLINICAL ASSESSMENT PRETREATMENT EVALUATION CLINICAL EVALUATION Superi sulcus tum See Treatment (NSCL-5) Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0-1; T3, N1) Optional wk-up: PFTs (if not previously done) Bronchoscopy Pathologic mediastinal lymph node evaluation Brain MRI MRI of spine + thacic inlet f superi sulcus lesions abutting the spine subclavian vessels PET/CT scan (if not previously done) Chest wall Proximal airway mediastinum See Treatment (NSCL-5) See Treatment (NSCL-5) Unresectable disease See Treatment (NSCL-5) Metastatic disease See Treatment f Metastasis solitary site (NSCL-12) distant disease (NSCL-14) Note: clinical stage IIB (T3 invasion,n0); stage IIIA ( T4 invasion,n0-1; T3,N1) 的病患原則上皆先執行 (1) Definite R/T (2) C/T (3) CCRT 再行評估是否可做手術切除 接續下頁 NSCL-4
6 CLINICAL PRESENTATION Superi sulcus tum (T3 invasion, N0-1) Superi sulcus tum (T4 extension, N0-1) Chest wall, proximal airway mediastinum (T3 invasion, N0-1 T4 extension, N0-1) Marginally resectable Unresectable INITIAL TREATMENT Preoperative concurrent chemadiation Preoperative concurrent chemadiation Definitive concurrent chemadiation Surgery (preferred) Concurrent chemadiation Chemotherapy Surgical reevaluation Resectable unresectsble Margins negative (R0) ADJUVANT TREATMENT Surgery + chemotherapy Surgery + chemotherapy Complete definitive RT + chemotherapy Chemotherapy if not given as initial treatment Surveillance (NSCL-13) Reresection + chemotherapy if not Surgery given as initial treatment Margins positive (R1, R2) Chemadiation+ chemotherapy if not given as initial treatment Stage IIIA (T4, N0-1) Definitive concurrent Surveillance Unresectable chemadiation (NSCL-13) Note: 延續上頁 clinical stage IIB (T3 invasion,n0); stage IIIA ( T4 invasion,n0-1; T3,N1) 的病患原則上皆先執行 (1) Definite R/T (2) C/T (3) CCRT 再行評估是否可做手術切除如果無法手術切除, 則繼續完成先前之化 放療 ; 如果可以手術切除, 則於術後接受化療 NSCL-5
7 CLINICAL ASSESSMENT PRETREATMENT EVALUATION MEDIASTINAL BIOPSY FINDINGS AND RESECTABILITY Stage IIIA (T1 3, N2) Options: PFTs Bronchoscopy Pathologic mediastinal lymph node evaluation PET/CT scan Brain MRI N2, N3 nodes negative N2 nodes positive N3 nodes positive Metastatic disease See Treatment T 1-3, N0-1 (NSCL-7) See Treatment (NSCL-7) See Stage IIIB (NSCL-10) See Treatment f Metastasis solitary site (NSCL-12) distant disease (NSCL-14) Separate pulmonary nodule(s) (Stage IIB, IIIA, IV) Options: PFTs (if not previously done) Bronchoscopy Pathologic mediastinal lymph node evaluation Brain MRI PET/CT scan (if not previously done) Separate pulmonary nodule(s), same lobe (T3, N0) ipsilateral non-primary lobe (T4, N0) Stage IV (N0, M1a): Contralateral lung (solitary nodule) Extrathacic metastatic disease See Treatment (NSCL-8) See Treatment (NSCL-8) See Treatment f Metastasis solitary site (NSCL-12) distant disease (NSCL-14) Note: 轉醫學中心執行縱膈腔淋巴結切片, 並評估是否可以進行手術切除 如無法手術切除, 則轉回本院進行 Definitive RT ± chemotherapy NSCL-6
8 MEDIASTINAL BIOPSY FINDINGS INITIAL TREATMENT ADJUVANT TREATMENT T1-3, N0-1 (including T3 with multiple nodules in same lobe) Surgery Resectable Unresectable Surgical resection + mediastinal lymph node dissection systematic lymph node sampling See Treatment accding to clinical stage (NSCL-1) N0 1 N2 Margins negative (R0) Margins positive (R1, R2) n See NSCL-3 Chemotherapy + RT Chemadiation n + chemotherapy T1-2, T3 ( 7 cm), N2 nodes positive k Brain MRI PET/CT scan, if not previously done Negative f M1 disease Positive Definitive concurrent chemadiation No apparent Surgery Induction chemotherapy ± RT See Treatment f Metastasis solitary site (NSCL-12) distant disease (NSCL-14) progression Progression Local Systemic ± chemotherapy ± RT(if not given) RT(if not given) ± chemotherapy See Treatment f Metastasis solitary site (NSCL-12) distant disease (NSCL -14) T3 (invasion), N2 nodes positive Brain MRI PET/CT scan, if not previously done Negative f M1 disease Positive Definitive concurrent chemadiation See Treatment f Metastasis solitary site (NSCL-12) distant disease (NSCL-14) n The panel recommends concurrent chemadiation f R2 resections and sequential chemadiation f R1 resection NSCL-7 Note: 轉醫學中心執行縱膈腔淋巴結切片, 並評估是否可以進行手術切除
9 CLINICAL PRESENTATION N0 1 See NSCL-3 f T3 NSCL-5 f T4 Separate pulmonary nodule(s), same lobe (T3, N0) ipsilateral non-primary lobe (T4, N0) Stage IV (N0, M1a): Contralateral lung (solitary nodule) Surgery N2 Treat as two primary lung tums if both curable Margins negative (R0) Margins positive (R1, R2) n See Evaluation (NSCL-1) Chemotherapy + RT Chemadiation n + chemotherapy Surveillance (NSCL-13) Surveillance (NSCL-13) Suspected multiple lung cancers (based on the presence of biopsyproven synchronous lesions histy of lung cancer) Chest CT with contrast PET-CT scan (if not previously done) Brain MRI Disease outside of chest No disease outside of chest See Systemic Therapy f Metastatic Disease (NSCL-15) Pathologic mediastinal lymph node g evaluation See Systemic Therapy N2-3 f Metastatic Disease (NSCL-15) N0-1 See Initial Treatment (NSCL-9 ) n The panel recommends concurrent chemadiation f R2 resections and sequential chemadiation f R1 resections. NSCL-8
10 CLINICAL PRESENTATION INITIAL TREATMENT Low risk of becoming symptomatic Observation Surveillance (NSCL-13) Multiple lesions Multiple lung cancers Asymptomatic Solitary lesion (metachronous disease) High risk of becoming symptomatic Definitive local therapy possible Parenchymal sparing resection (preferred) Radiation Ablation Symptomatic Definitive local therapy not possible Consider palliative chemotherapy ± local palliative therapy See Systemic Therapy f Metastatic Disease (NSCL-15) I See Principles of Radiation Therapy (NSCL-B). NSCL-9
11 CLINICAL ASSESSMENT PRETREATMENT EVALUATION INITIAL TREATMENT Stage IIIB (T1 3, N3) PFTs (if not previously done) PET/CT scan (if not previously done) Brain MRI Pathologic confirmation of N3 disease by either: (optional) Mediastinoscopy Supraclavicular lymph node biopsy Thacoscopy Needle biopsy Mediastinotomy EUS/EBUS Bx N3 negative N3 positive Metastatic disease See Initial treatment f stage I IIIA (NSCL-7) Definitive concurrent chemadiation s See Treatment f Metastasis solitary site (NSCL-12) distant disease (NSCL-14) s If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 4 cycles of full-dose chemotherapy. NSCL-10
12 CLINICAL ASSESSMENT Stage IIIB (T4 extension, N2 3) PRETREATMENT EVALUATION PET/CT scan (if not previously done) Brain MRI Pathologic confirmation of N2 3 disease by either: (optional) Mediastinoscopy Supraclavicular lymph node biopsy Thacoscopy Needle biopsy Mediastinotomy EUS/EUBS Bx Contralateral mediastinal node negative Contralateral mediastinal node positive (T4, N3) Metastatic disease Ipsilateral mediastinal node negative (T4, N0-1) Ipsilateral mediastinal node positive (T4, N2) INITIAL TREATMENT See Treatment f Stage IIIA (NSCL-7) Definitive concurrent chemadiation s Definitive concurrent chemadiation s See Treatment f Metastasis solitary site (NSCL-12) distant disease (NSCL-14) Stage IV, M1a: pleural pericardial effusion Thacentesis pericardiocentesis ± thacoscopy if thacentesis indeterminate Negative Positive See Treatment accding to TNM stage (NSCL-7) Local therapy if necessary (eg, pleurodesis, ambulaty small catheter drainage, pericardial window) + treatment as f stage IV disease (NSCL-12) s If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 4 cycles of full-dose chemotherapy. NSCL-11
13 CLINICAL ASSESSMENT Stage IV, M1b: solitary site PRETREATMENT EVALUATION Pathologic mediastinal lymph node evaluation Bronchoscopy Brain MRI PET/CT scan (if not previously done) Brain y Adrenal Pathologic diagnosis by needle resection INITIAL TREATMENT Surgical resection, followed by whole brain RT (WBRT) (categy 1) stereotactic radiosurgery (SRS) SRS + WBRT (categy 1 f one metastasis) SRS alone T1-2, N0-1; T3, N0 Local therapy f adrenal T1-2, N2; lesion (if lung lesion curable, T3, N1-2; based on T and N stage) Any T, N3; T4, Any N See Systemic Therapy f Metastatic Disease (NSCL-15) Surgical resection of lung lesion Stereotactic ablative radiotherapy (SABR) of lung lesion Chemotherapy Chemotherapy Surgical resection of lung lesion See Systemic Therapy f Metastatic Disease (NSCL-15) NSCL-12
14 SURVEILLANCE Non-small cell lung cancer Guideline, version /05 Locegional recurrence See Therapy f Recurrence and Metastasis (NSCL-14) No evidence of clinical/radiographic disease), stages I-IV: H&P and chest CT ± contrast every 6-12 mo f 2 y (categy 2B), then H&P and a non-contrastenhanced chest CT annually (categy 2B) Smoking cessation advice, counseling, and pharmacotherapy PET brain MRI is not indicated See Cancer Survivship Care (NSCL-G). Distant metastases See Therapy f Recurrence and Metastasis (NSCL-14) NSCL-13
15 THERAPY FOR RECURRENCE AND METASTASIS Non-small cell lung cancer Guideline, version /05 Endobronchial obstruction Laser/stent/other surgery External-beam RT brachytherapy Photodynamic therapy Locegional recurrence Resectable recurrence Mediastinal lymph node recurrence Reresection (preferred) External-beam RT SABR Concurrent chemadiation (if RT not previously given) No evidence of disseminated disease Observation Systemic chemotherapy (categy 2B) Superi vena cava (SVC) obstruction Concurrent chemadiation (if not previously given) External-beam RT SVC stent Evidence of disseminated disease See Systemic Therapy f Metastatic Disease (NSCL-15) Severe hemoptysis External-beam RT brachytherapy Laser photodynamic therapy embolization Surgery Localized symptoms Palliative external-beam RT Distant metastases Diffuse brain metastases Bone metastasis Palliative external-beam RT Palliative external-beam RT + thopedic stabilization, if risk of fracture Consider bisphosphonate therapy denosumab See Systemic Therapy f Metastatic Disease (NSCL-15) Solitary metastasis See pathway f Stage IV, M1b, solitary site (NSCL-12) Disseminated metastases See Systemic Therapy f Metastatic Disease (NSCL-15) i NSCL-14
16 SYSTEMIC THERAPY FOR METASTATIC DISEASE --- HISTOLOGIC SUBTYPE EGFR mutation ALK negative See First-Line Therapy (NSCL-16) Adenocarcinoma Large Cell NSCLC NOS EGFR mutation testing ALK testing EGFR mutation positive See First-Line Therapy (NSCL -17) Metastatic Disease Establish histologic subtype with adequate tissue f molecular testing Smoking cessation counseling ALK positive See First-Line Therapy (NSCL-17) Squamous cell carcinoma EGFR mutation and ALK testing are not routinely recommended except in never smokers and small biopsy specimens ee See First-Line Therapy (NSCL -18) NSCL-15
17 . ADENOCARCINOMA, LARGE CELL, NSCLC NOS: EGFR MUTATION AND ALK NEGATIVE Non-small cell lung cancer Guideline, version /05 FIRST-LINE THERAPY RESPONSE EVALUATION MAINTENANCE THERAPY PS 0-1 PS 2 PS 3-4 Doublet chemotherapy Bevacizumab + chemotherapy (if criteria met) Cisplatin/pemetrexed (if criteria met) Cetuximab/vinelbine/cisplatin Chemotherapy Best supptive care only (See NCCN Guidelines f Palliative Care) Tum response evaluation Progression Tum response stable disease 4-6 cycles (total) Tum response evaluation See Second-line Therapy (NSCL-19) Progression Tum response Continuation of current regimen until disease progression Continuation maintenance bevacizumab cetuximab pemetrexed bevacizumab + pemetrexed NSCL-16
18 ADENOCARCINOMA, LARGE CELL, NSCLC NOS: EGFR MUTATION OR ALK POSITIVE FIRST-LINE THERAPY EGFR mutation positive EGFR mutation discovered pri to first-line chemotherapy EGFR mutation discovered during first-line chemotherapy Erlotinib Switch maintenance: erlotinib May add erlotinib to current chemotherapy Progression Progression Symptomatic Asymptomatic Brain Systemic Isolated lesion Multiple lesions Isolated lesion Multiple lesions Consider local therapy and continue erlotinib Consider WBRT and continue erlotinib Consider local therapy and continue erlotinib Consider systemic therapy ± erlotinib Continue erlotinib ALK positive Crizotinib Progression See Second-line Therapy (NSCL-19) NSCL-17
19 SQUAMOUS CELL CARCINOMA FIRST-LINE THERAPY RESPONSE EVALUATION MAINTENANCE THERAPY PS 0-1 Doublet chemotherapy Cetuximab/vinelbine/ cisplatin Tum response evaluation Progression See Second-line Therapy (NSCL-19) Progression PS 2 Chemotherapy Tum response stable disease PS 3-4 Best supptive care 4-6 cycles (total) Tum response evaluation Tum response stable disease Continuation of current regimen until disease progression Continuation maintenance cetuximab gemcitabine Switch maintenance erlotinib docetaxel Close observation NSCL-18
20 ADENOCARCINOMA, LARGE CELL, NSCLC NOS, SQUAMOUS CELL CARCINOMA SECOND-LINE THERAPY THIRD-LINE THERAPY Perfmance status 0-2 Docetaxel Pemetrexed (nonsquamous) Erlotinib Platinum doublet ± bevacizumab (if erlotinib crizotinib given as first-line and nonsquamous histologic type) Progression Perfmance status 0-2 Perfmance status 3-4 If not already given: Docetaxel Pemetrexed (nonsquamous) Erlotinib Erlotinib Progression Best supptive care only Perfmance status 0-2 Perfmance status 3, 4 Best supptive care Clinical trial Best supptive care only Perfmance status 3-4 Erlotinib Best supptive care only SCL-19
21 CHEMOTHERAPY REGIMENS Non-small cell lung cancer Guideline, version /05 癌別 :Non-small cell lung cancer Adjuvant 最近改版日期 2013/05 (1) Alimta ± Cisplatin regimen (every 21 days) -Alimta 500 mg/m2 IVD D1 -Cisplatin mg/m2 IV D1 (2)Gemcitabine ± Cisplatin regimen (every 28 days) -Gemcitabine 1000mg/m2 IVD D1,8,15 -Cisplatin mg/m2 IV D15 (3) Taxotere ± Cisplaitn regimen (every 28 days) -Taxotere mg/m2 IV D1,8,15 處方內容 -Cisplatin mg/m2 IV D15 (4) Taxol ± Cisplatin regimen (every 28 days) -Taxol mg/m2 IV D1,8,15 -Cisplatin mg/m2 IV D15 (5) Navelbine ± Cisplaitn regimen(every 28 days) -Navelbine mg/m2 IVD1,8,15 Oral Navelbine 60mg/m2 D1,8,15 -Cisplatin mg/m2 IV D15 Neoadjuvant 最近改版日期 2013/05 (1) Alimta ± Cisplatin regimen (every 21 days) -Alimta 500 mg/m2 IVD D1 -Cisplatin mg/m2 IV D1 (2)Gemcitabine ± Cisplatin regimen (every 28 days) -Gemcitabine 1000mg/m2 IVD D1,8,15 -Cisplatin mg/m2 IV D15 (3) Taxotere ± Cisplaitn regimen (every 28 days) -Taxotere mg/m2 IV D1,8,15 處方內容 -Cisplatin mg/m2 IV D15 (4) Taxol ± Cisplatin regimen (every 28 days) -Taxol mg/m2 IV D1,8,15 -Cisplatin mg/m2 IV D15 (5) Navelbine ± Cisplaitn regimen(every 28 days) -Navelbine mg/m2 IVD1,8,15 Oral Navelbine 60mg/m2 D1,8,15 -Cisplatin mg/m2 IV D15
22 CCRT 最近改版日期 2013/05 (1) Monotherapy : - weekly Gemcitabine mg/M2 (2) Combination: 處方內容 - weekly (Gemcitabine 300mg/M2 + Cisplatin20mg/M2 )
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationCervical Cancers Treatment Guideline KMHK
Cervical Cancers Treatment Guideline KMHK 子宮頸癌修訂紀錄 修訂日期修訂內容摘要 修訂頁次 版本 97 年 98 年 99 年 100 年 101 年 102 年 103 年 104 年 子宮頸癌診療指引新制訂新增子宮頸篩檢凖則多科會議討論檢視後未修改多科會議討論檢視後未修改多科會議討論檢視後未修改多科會議討論檢視後未修改 ;stage Ia1 做 simple
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationNon-Small Cell Lung Cancer
Small Cell NCCN Lung Table Guidelines of Contents Index Staging, NSCLC, Table of References Contents NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Small Cell Lung Cancer Version
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More information制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識
2006.03.09 制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識 2007.10.01 修訂 2009.04.22 修訂 2010.04.07 審閱 LCIS (Lobular Carcinoma in Situ) 2011.12.07 修訂 2012.03.07 修訂 Diagnosis Workup Risk Reduction Surveillance Biopsy
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationNon-Small Cell Lung Cancer
Small Cell NCCN Lung Table Guidelines of Contents Index Staging, NSCLC, Table of References Contents NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Small Cell Lung Cancer Version
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationNCCN Guidelines for Patients
Non-Small Cell Lung Cancer NCCN Guidelines for Patients Version 2010 In honor and memory of Dana Reeve Also available at NCCN.com Non-Small Cell Lung Cancer Table of Contents Map of the NCCN Member Institutions...
More informationCollecting Cancer Data: Lung
Collecting Cancer Data: Lung NAACCR 2011 2012 Webinar Series 2/2/2012 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationSpecial Treatment Issues in Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationNon-Small Cell Lung Cancer
Clinical in Oncology Non-Small Cell Lung Cancer V.1.2010 Continue www.nccn.org * David S. Ettinger, MD/Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Panel Members Thierry Jahan,
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationLung and Aerodigestive malignancies
Lung and Aerodigestive malignancies Nabil F Saba MD, FACP Professor, Director of the Head and Neck Oncology Program, Winship Cancer Institute Emory University COI I am a consultant for GSK, Merck, BMS,
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More information3/30/2009 Lung Cancer Deaths 2008 Lung Cancer Deaths Lung Cancer Deaths--Males Males 5
LUNG CANCER 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Very common Very lethal Lung Cancer Median age of diagnosis approximately 70 years, but affects all ages(even pediatric!) Advances in
More informationLung Cancer Incidence 2008 Lung Cancer Deaths-Males 2008 Incidence Total U.S.(all types): 1,437,180 Lung Cancer Deaths-Females Lung cancer 215,000(15%
Multidisciplinary approach 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Neurology Neurosurgery Orthopedic surgery General surgery Vascular surgery Gastroenterology Cardiology Lung Cancer Very
More informationLung 8/7/14. Collecting Cancer Data: Lung NAACCR Webinar Series. August 7, 2014
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More information本院臨床指引乃根據 NCCN guideline 2015 V1 及 Japanese Gastric Cancer Association Guideline 2010 V3, 經多學科團隊論會共同修訂完成
前言 本院臨床指引乃根據 NCCN guideline 2015 V1 及 Japanese Cancer Association Guideline 2010 V3, 經多學科團隊論會共同修訂完成 制定人員 : 腫瘤內科 : 林育靖醫師 鄧仲仁醫師一般外科 : 吳建明醫師腸胃內科 : 梁程超醫師 林政寬醫師放射腫瘤 : 謝忱希醫師 徐晨雄醫師組織病理 : 黃文志醫師影像醫學 : 謝詔裕醫師核子醫學
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationLung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the highest incidence
LUNG CANCER 2010 Mark B. Stoopler, M.D. Division of Medical Oncology Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationWHITE PAPER - SRS for Non Small Cell Lung Cancer
WHITE PAPER - SRS for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from
More informationThe 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationNon-Small Cell Lung Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Small Cell Lung Cancer Version 4.2016 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version 4.2016,
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationLung Cancer Case Study
Lung Cancer Case Study Presented by s GP Education Programme 2 Part One Initial presentation 60 year old lady, presents with a 6 week history of right sided chest pain. The pain is like a dull ache, but
More informationTraditional Approaches to Treating NSCLC, Part 2: Neoadjuvant Combined Modality, Locally Advanced, and Metastatic NSCLC
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationNon-Small Cell Lung Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Small Cell Lung Cancer Version 2.2018 December 19, 2017 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationGUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
More informationLung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.
Lung Case Scenario 1 A 54 year white male presents with a recent abnormal CT of the chest. The patient has a history of melanoma, kidney, and prostate cancers. 10/24/13 Chest X-ray: 2.9 cm mass like density
More informationUNDERSTANDING SQUAMOUS CELL LUNG CANCER
UNDERSTANDING SQUAMOUS CELL LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure This brochure
More informationNon-Small Cell Lung Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Small Cell Lung Cancer Version 4.2018 April 26, 2018 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue
More informationCase Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12
Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer Doug Rahn 6/1/12 Outline I. Presentation of Case II. Epidemiology III. Staging IV. Review of Literature V. Recommendations VI.
More informationSurveillance and outcome of liver metastasis in patients with colorectal cancer who had undergone curative-intent operation
O R I G I N A L A R T I C L E KC Cheng YP Yeung Patrick YY Lau William CS Meng 鄭繼志楊玉鵬劉應裕蒙家興 Surveillance and outcome of liver metastasis in patients with colorectal cancer who had undergone curative-intent
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationLung Cancer Update. HARMESH R NAIK, MD. February 28, 2001
Lung Cancer Update HARMESH R NAIK, MD. February 28, 2001 Progress update Prevention Screening Staging Treatment Epidemiology Estimated 169,500 new cases Estimated 157,400 deaths Second commonest cancer
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationAdjuvant treatment Tamoxifen for 5 years ER or uncertain Risk reduction for contralateral breast cancer optional AI may also be considered
共識診斷 臨床檢查 主要治療 輔助治療 術後追蹤 DCIS TisN0M0 LCIS TisN0M0 ER/PR/Her-2 ER/PR/Her-2 1. Partial mastectomy SLNB whole breast radiation therapy 2. Total mastectomy SLNB reconstruction Risk reduction surgery Adjuvant
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationLung Cancer: Diagnosis, Staging and Treatment
PATIENT EDUCATION patienteducation.osumc.edu Lung Cancer: Diagnosis, Staging and Treatment Cancer starts in your cells. Cells are the building blocks of your tissues. Tissues make up the organs of your
More information乳癌化療指引. Breast Cancer
乳癌化療指引 103 年 12 月第五版 99-102 年, 第一至四版 注意事項 : 本院癌症團隊基於實證醫學制定此化學治療指引 : 本院癌症團隊基於實證醫學制定此化學治療指引, 實證醫學之結論源自臨床詴驗, 實證醫學之結論源自臨床詴驗, 惟參與臨床詴驗之研究對象多以 70 歲以下之病人為主, 故建議 70 歲以上病人接受治療時, 應依據病人實際臨床狀況進行抗癌藥物劑量之調整! 健保藥品給付限制註記說明
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationNon-Small Cell Lung Cancer
Clinical in Oncology Non-Small Cell Lung Cancer V.2.2009 Continue www.nccn.org * David S. Ettinger, MD/Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Wallace Akerley, MD Huntsman
More informationThe International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationEnterprise Interest None
Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationFDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.
FDG PET/CT in Lung Cancer Read with the experts Homer A. Macapinlac, M.D. Patient with suspected lung cancer presents with left sided chest pain T3 What is the T stage of this patient? A) T2a B) T2b C)
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationLung Cancer: Overview and Updates
Lung Cancer: Overview and Updates Peter H. Johnson, M.D. Medical Oncologist & Hematologist, Columbia St. Mary s Hospital February 1, 2018 Disclosures No financial interests to disclose No conflicts of
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationCervical Cancer 3/25/2019. Abnormal vaginal bleeding
Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms
More informationINTERACTIVE SESSION 2
INTERACTIVE SESSION 2 2 patients with lung metastases, with complete response after oncologic treatment - Clinical Case Presentation: Dr. Esther Casado Dr. Sergi Call - Expert Opinion: Dr. Raúl Embún Dr.
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationMedical Management of Non-Small Cell Lung Cancer
Medical Management of Non-Small Cell Lung Cancer GS Bhattacharyya, D Sarkar Consultant Medical Oncologist and Clinical Haematologist, B.R. Singh Hospital, Eastern Railway & Institute of Pulmocare, Kolkata;
More informationNon-Small Cell Lung Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Small Cell Lung Cancer Version 8.2017 July 14, 2017 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue
More information新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方
新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方 文件修訂記錄 修正次數 修正日期 修正版別 修 改 內 容 1 2011.04.07 1.0 初次訂定 2 2013.05.08 2.0 修訂 3 2013.04.30 3.0 修訂 :Triple-Negative Breast Cancer 處方 新增 :Neoadjuvant-p7~8 4 2014.04.29 4.0 修訂 :FEC + Trastuzumab
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationHistopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
More informationLung Cancer in Older Adults.. 2 Cases
Lung Cancer in Older Adults.. 2 Cases Cancer in the Older Person Individualised management + Dr Christopher Steer Border Medical Oncology Albury-Wodonga Inaugural Chair Geriatric Oncology Interest Group
More informationTable 1 Major Classifications of Lung Cancer. Non Small Cell Lung Cancer Adenocarcinoma
VIII LUNG CANCER Jeffrey Crawford, m.d. Definition and Classifications Bronchogenic carcinoma of the lung lung cancer comprises a group of malignant neoplasms that arise from bronchial epithelium. The
More information